ACE Overexpression in Myelomonocytic Cells: Effect on a Mouse Model of Alzheimer’s Disease (original) (raw)

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

1. Skeggs Jr LT. Discovery of the two angiotensin peptides and the angiotensin converting enzyme. Hypertension. 1993;21:259–60.
   Article PubMed Google Scholar
2. Skeggs Jr LT, Kahn JR, Shumway NP. The preparation and function of the hypertensin-converting enzyme. J Exp Med. 1956;103:295–9.
   Article CAS PubMed Central PubMed Google Scholar
3. Bernstein KE, Ong FS, Blackwell W-LB, Shah KH, Giani JF, Gonzalez-Villalobos RA, et al. A modern understanding of the traditional and non-traditional biological functions of angiotensin converting enzyme (ACE). Pharmacol Rev. 2013;65:1–46. This is a very complete review of the physiology and biochemistry of ACE.
   Article CAS PubMed Central PubMed Google Scholar
4. Krege JH, John SW, Langenbach LL, Hodgin JB, Hagaman JR, Bachman ES, et al. Male-female differences in fertility and blood pressure in ACE deficient mice. Nature. 1995;375:146–8.
   Article CAS PubMed Google Scholar
5. Esther Jr CR, Howard TE, Marino EM, Goddard JM, Capecchi MR, Bernstein KE. Mice lacking angiotensin-converting enzyme have low blood pressure, renal pathology, and reduced male fertility. Lab Investig. 1996;74:953–65.
   CAS PubMed Google Scholar
6. Miyazaki Y, Tsuchida S, Nishimura H, Pope 4th JC, Harris RC, McKanna JM, et al. Angiotensin induces the urinary peristaltic machinery during the perinatal period. J Clin Invest. 1998;102:1489–97. This seminal study demonstrates a critical role of angiotensin II in peristaltic movement of urine by the ureter. In the absence of angiotensin II, pressure within the ureter increases and causes kidney damage.
   Article CAS PubMed Central PubMed Google Scholar
7. Esther Jr CR, Marino EM, Howard TE, Corvol P, Capecchi MR, Bernstein KE. The critical role of tissue angiotensin converting enzyme (ACE) as revealed by gene targeting in mice. J Clin Invest. 1997;99:2375–85.
   Article CAS PubMed Central PubMed Google Scholar
8. Hashimoto S, Adams JW, Bernstein KE, Schnermann J. Micropuncture determination of nephron function in mice without tissue angiotensin-converting enzyme. Am J Physiol Ren Physiol. 2005;288:F445–52.
   Article CAS Google Scholar
9. Cole J, Ertoy D, Lin H, Sutliff RL, Ezan E, Guyene TT, et al. Lack of angiotensin II-facilitated erythropoiesis causes anemia in angiotensin-converting enzyme-deficient mice. J Clin Invest. 2000;106:1391–8.
   Article CAS PubMed Central PubMed Google Scholar
10. Lin C, Datta V, Okwan-Duodu D, Chen X, Fuchs S, Alsabeh R, et al. Angiotensin-converting enzyme is required for normal myelopoiesis. FASEB J. 2011;25:1145–55. A study showing that the lack of ACE is associated with developmental defects in myelopoiesis.
    Article CAS PubMed Central PubMed Google Scholar
11. Shen XZ, Billet S, Lin C, Okwan-Duodu D, Chen X, Lukacher AE, et al. The carboxypeptidase ACE shapes the MHC class I peptide repertoire. Nat Immunol. 2011;12:1078–85. The first study showing that ACE plays a role in generating the MHC class I peptide repertoire.
    Article CAS PubMed Central PubMed Google Scholar
12. Eisenlohr LC, Bacik I, Bennink JR, Bernstein K, Yewdell JW. Expression of a membrane protease enhances presentation of endogenous antigens to MHC class I-restricted T lymphocytes. Cell. 1992;71(6):963–72.
    Article CAS PubMed Google Scholar
13. Shen XZ, Li P, Weiss D, Fuchs S, Xiao HD, Adams JW, et al. Mice with enhanced macrophage angiotensin converting enzyme are resistant to melanoma. Am J Pathol. 2007;170:2122–34. The original publication describing the ACE 10/10 mice.
    Article CAS PubMed Central PubMed Google Scholar
14. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25:677–86.
    Article CAS PubMed Google Scholar
15. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005;5:953–64.
    Article CAS PubMed Google Scholar
16. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141:39–51.
    Article CAS PubMed Google Scholar
17. Shen XZ, Okwan-Duodu D, Billet S, Lin C, Ong FS, Bernstein E, et al. Over-expression of angiotensin converting enzyme in myelomonocytic cells alters tumor-induced myeloid-mediated immunosuppression. Lab Investig. 2014. doi:10.1038/labinvest.2014.41.
    PubMed Central Google Scholar
18. Okwan-Duodu D, Datta V, Shen XZ, Goodridge HS, Bernstein EA, Fuchs S, et al. Angiotensin-converting enzyme overexpression in mouse myelomonocytic cells augments resistance to Listeria and methicillin-resistant Staphylococcus aureus. J Biol Chem. 2010;285:39051–60.
    Article CAS PubMed Central PubMed Google Scholar
19. McLaren JE, Michael DR, Ashlin TG, Ramji DP. Cytokines, macrophage lipid metabolism and foam cells: implications for cardiovascular disease therapy. Prog Lipid Res. 2011;50:331–47.
    Article CAS PubMed Google Scholar
20. 2013 Alzheimer's disease facts and figures. http://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=2&ved=0CD4QFjAB&url=http%3A%2F%2Fwww.alz.org%2Fdownloads%2Ffacts_figures_2013.pdf&ei=5yEVU5GlOdTsoATTnYLwBQ&usg=AFQjCNGgHwQODpp8E9COQkN1aoqhqye8YQ&sig2=BfCoPWHQtTctw7CHyI9nnA&bvm=bv.62333050,d.cGU
21. Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology. 2013;80:1778–83.
    Article PubMed Central PubMed Google Scholar
22. Selkoe DJ. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res. 2008;192:106–13.
    Article CAS PubMed Central PubMed Google Scholar
23. Beyreuther K, Masters CL. Alzheimer's disease. The ins and outs of amyloid-beta. Nature. 1997;389(6652):677–8.
    Article CAS PubMed Google Scholar
24. Armstrong RA. Beta-amyloid plaques: stages in life history or independent origin? Dement Geriatr Cogn Disord. 1998;9(4):227–38.
    Article CAS PubMed Google Scholar
25. Zhang H, Ma Q, Zhang YW, Xu H. Proteolytic processing of Alzheimer's β-amyloid precursor protein. J Neurochem. 2012;120 suppl 1:9–21.
    Article CAS PubMed Central PubMed Google Scholar
26. Saido TC. Alzheimer's disease as proteolytic disorders: anabolism and catabolism of beta-amyloid. Neurobiol Aging. 1998;19(1 Suppl):S69–75.
    Article CAS PubMed Google Scholar
27. Potter R, Patterson BW, Elbert DL, Ovod V, Kasten T, Sigurdson W, et al. Increased in vivo amyloid-beta42 production, exchange, and loss in presenilin mutation carriers. Sci Transl Med. 2013;5(189):189ra77.
    Article PubMed Google Scholar
28. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, et al. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science (New York, NY). 2010;330(6012):1774.
    Article CAS Google Scholar
29. Koronyo-Hamaoui M, Ko MK, Koronyo Y, Azoulay D, Seksenyan A, Kunis G, et al. Attenuation of AD-like neuropathology by harnessing peripheral immune cells: local elevation of IL-10 and MMP-9. J Neurochem. 2009;111(6):1409–24. First demonstration of increased natural migration of blood-borne macrophages into the brain of mouse models of AD following MOG45D immunization. The macrophages in the immunized mice were observed to accumulate surrounding the plaque and to phagocytose Aβ. This was associated with lower TNF-α, and increased IL-10 and MMP-9 levels in the brain.
    Article CAS PubMed Google Scholar
30. Rezai-Zadeh K, Gate D, Gowing G, Town T. How to get from here to there: macrophage recruitment in Alzheimer's disease. Curr Alzheimers Res. 2011;8(2):156–63.
    Article CAS Google Scholar
31. Hemming ML, Selkoe DJ. Amyloid β-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem. 2005;280(45):37644–50.
    Article CAS PubMed Central PubMed Google Scholar
32. Zou K, Yamaguchi H, Akatsu H, Sakamoto T, Ko M, Mizoguchi K, et al. Angiotensin-converting enzyme converts amyloid β-protein 1-42 (Aβ(1-42)) to Aβ(1-40), and its inhibition enhances brain Aβ deposition. J Neurosci. 2007;27:8628–35.
    Article CAS PubMed Google Scholar
33. Sun X, Becker M, Pankow K, Krause E, Ringling M, Beyermann M, et al. Catabolic attacks of membrane-bound angiotensin-converting enzyme on the N-terminal part of species-specific amyloid-β peptides. Eur J Pharmacol. 2008;588(1):18–25.
    Article CAS PubMed Google Scholar
34. Zou K, Maeda T, Watanabe A, Liu J, Liu S, Oba R, et al. Aβ42-to-Aβ40- and angiotensin-converting activities in different domains of angiotensin-converting enzyme. J Biol Chem. 2009;284(46):31914–20.
    Article CAS PubMed Central PubMed Google Scholar
35. Bernstein KE, Koronyo Y, Salumbides BC, Sheyn J, Pelissier L, Lopes DH, et al. Angiotensin-converting enzyme overexpression in myelomonocytes prevents Alzheimer's-like cognitive decline. J Clin Invest. 2014;124:1000–12. A detailed study examining ACE 10/10 mice crossed with mice genetically predisposed to Alzheimer's-like disease. The ACE 10/10 phenotype markedly ameliorates the AD-like pathology and maintains cognition at wild type levels.
    Article CAS PubMed Central PubMed Google Scholar
36. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer's disease. Neurobiol Aging. 2000;21(3):383–421.
    Article CAS PubMed Central PubMed Google Scholar
37. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med. 2006;12(9):1005–15.
    CAS PubMed Google Scholar
38. Das P, Golde T. Dysfunction of TGF-beta signaling in Alzheimer's disease. J Clin Invest. 2006;116(11):2855–7.
    Article CAS PubMed Central PubMed Google Scholar
39. Zhang YY, Fan YC, Wang M, Wang D, Li XH. Atorvastatin attenuates the production of IL-1β, IL-6, and TNF-α in the hippocampus of an amyloid β1-42-induced rat model of Alzheimer's disease. Clin Interv Aging. 2013;8:103–10.
    CAS PubMed Central PubMed Google Scholar
40. Weller RO, Nicoll JA. Cerebral amyloid angiopathy: pathogenesis and effects on the ageing and Alzheimer brain. Neurol Res. 2003;25(6):611–6.
    Article PubMed Google Scholar
41. Attems J, Quass M, Jellinger KA, Lintner F. Topographical distribution of cerebral amyloid angiopathy and its effect on cognitive decline are influenced by Alzheimer disease pathology. J Neurol Sci. 2007;257(1–2):49–55.
    Article PubMed Google Scholar
42. De Reuck J, Deramecourt V, Cordonnier C, Leys D, Maurage CA, Pasquier F. The impact of cerebral amyloid angiopathy on the occurrence of cerebrovascular lesions in demented patients with Alzheimer features: a neuropathological study. Eur J Neurol. 2011;18(6):913–8.
    Article PubMed Google Scholar
43. Holland CM, Smith EE, Csapo I, Gurol ME, Brylka DA, Killiany RJ, et al. Spatial distribution of white-matter hyperintensities in Alzheimer disease, cerebral amyloid angiopathy, and healthy aging. Stroke J Cereb Circ. 2008;39(4):1127–33.
    Article Google Scholar
44. Miao J, Vitek MP, Xu F, Previti ML, Davis J, Van Nostrand WE. Reducing cerebral microvascular amyloid-beta protein deposition diminishes regional neuroinflammation in vasculotropic mutant amyloid precursor protein transgenic mice. J Neurosci. 2005;25(27):6271–7.
    Article CAS PubMed Google Scholar
45. Kehoe PG, Miners S, Love S. Angiotensins in Alzheimer's disease - friend or foe? Trends Neurosci. 2009;32:619–28.
    Article CAS PubMed Google Scholar
46. Kehoe PG, Passmore PA. The renin-angiotensin system and antihypertensive drugs in Alzheimer's disease: current standing of the angiotensin hypothesis? J Alzheimers Dis. 2012;30:S251–68. An excellent review discussing the relationship of hypertension and anti-hypertensive medications to the risk of developing Alzheimer's disease.
    PubMed Google Scholar

Download references